Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.47 |
| ▸ | GSR | P00390 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271385 | 1.00 | MAPT (0.53) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL29364858 | 0.81 | MAPT (0.50) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL56616 | 0.81 | MAPT (0.50) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL6990761 | 0.79 | MAPT (0.49) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL17434625 | 0.79 | MAPT (0.49) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL9669573 | 0.78 | GPR35 (0.46) | MAPTTDP1L3MBTL1HTTTSHR | |
| SCHEMBL11409567 | 0.78 | MAPT (0.47) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL3273393 | 0.78 | TXNRD1 (0.50) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL29392605 | 0.78 | MERTK (0.51) | MAPTTDP1POLBL3MBTL1MERTK | |
| SCHEMBL381701 | 0.78 | MERTK (0.51) | MAPTTDP1POLBL3MBTL1MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| WO-2024182747-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4353324-A2 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013061005-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012177893-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177893-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-1998045267-A1 | AMINOPYRIDINE DERIVATIVES FOR INFLAMMATORY AND MALIGNANT DISEASES | FERRING B.V. (NL) | 1998-10-15 | — | — | WO | disclosed |
| US-4547218-A | Certain 3-nitro-6-phenoxy-2-pyridyl-oxy-propionates having herbicidal activity | THE DOW CHEMICAL COMPANY (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0109751-A1 | Compounds and method for selectively controlling weeds in the presence of valuable crops | THE DOW CHEMICAL COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | MAPT 3264/4885TDP1 498/4885POLB 2812/4885 |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | MAPT 3264/4885TDP1 498/4885POLB 2812/4885 |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | AHR, ARNT, AIPL1 | MAPT 4503/4885TDP1 3078/4885POLB 3733/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | MAPT 4647/4885TDP1 3301/4885POLB 4089/4885 |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | MAPT 2168/4885TDP1 375/4885POLB 386/4885 |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | MAPT 3264/4885TDP1 498/4885POLB 2812/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | MAPT 3264/4885TDP1 498/4885POLB 2812/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | MAPT 800/4885TDP1 2636/4885POLB 4413/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | MAPT 3264/4885TDP1 498/4885POLB 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.